This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Moretti, R. Articles by Bava, A. Search for Related Content PubMed PubMed Citation Articles by Moretti, R. Articles by Bava, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Alzheimer's Disease Dementia Social Bookmarking                   What's this?

Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: A 24-month follow-up of 68 patients

Dipartimento di Fisiologia e Patologia Generale, Università degli Studi di Trieste; Dipartimento di Medicina Clinica e Neurologia, U.C.O. di Clinica Neurologica, Ambulatorio Disturbi Cognitivi, Università degli Studi di Trieste, Trieste, Italy.

Paola Torre, MD

Rodolfo M. Antonello, MD

Dipartimento di Medicina Clinica e Neurologia, U.C.O. di Clinica Neurologica, Ambulatorio Disturbi Cognitivi, Università degli Studi di Trieste, Trieste, Italy.

Giuseppe Cazzato, MD

Dipartimento di Medicina Clinica e Neurologia, U.C.O. di Clinica Neurologica,Università degli Studi di Trieste, Trieste, Italy.

Stefania Griggio, MD

Dipartimento di Medicina Clinica e Neurologia, U.C.O. di Clinica Neurologica, Ambulatorio Disturbi Cognitivi, Università degli Studi di Trieste, Trieste, Italy.

Antonio Bava, MD

Dipartimento di Fisiologia e Patologia Generale, Università degli Studi di Trieste, Trieste, Italy.

Although the core feature of all types of dementia is progressive cognitive disruption, most demented patients also express noncognitive behavioral problems. These noncognitive problems lead to potentially devastating disabilities, and are often a major cause of stress, anxiety and concern for caregivers. Psychotropic drugs are frequently used to control these symptoms, but they have the potential for significant side effects, such as sedation, disinhibition, depression, falls, incontinence, parkinsonisms and akathisias. For 24 months, we monitored 68 outpatients suffering from Alzheimer's disease, vascular dementia, frontal lobe dementia, Parkinson dementia complex, and Lewy body disease. Our purpose was to identify the role and efficacy of olanzapine and the side effects which emerged during the treatment of behavioral alteration resulting from five etiological causes. This paper will discuss the results of this study, and will provide an overview of the existing literature.

Key Words: Alzheimer's disease • vascular dementia • frontal lobe dementia • Parkinson's dementia complex • Lewy body disease • delusions • agitation • olanzapine

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 18, No. 4, 205-214 (2003)
DOI: 10.1177/153331750301800410


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A D Hutchinson and J L Mathias Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review J. Neurol. Neurosurg. Psychiatry, September 1, 2007; 78(9): 917 - 928. [Abstract] [Full Text] [PDF]

				M. L. Onor, M. Saina, and E. Aguglia Efficacy and Tolerability of Quetiapine in the Treatment of Behavioral and Psychological Symptoms of Dementia American Journal of Alzheimer's Disease and Other Dementias, January 1, 2007; 21(6): 448 - 453. [Abstract] [PDF]

				R. Moretti, P. Torre, R. M. Antonello, T. Cattaruzza, G. Cazzato, and A. Bava Olanzapine as a possible treatment for anxiety due to vascular dementia: An open study American Journal of Alzheimer's Disease and Other Dementias, March 1, 2004; 19(2): 81 - 88. [Abstract] [PDF]